Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued on Friday. The firm set a “hold” rating on the medical research company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th.

Cytosorbents Trading Up 2.6 %

CTSO opened at $0.88 on Friday. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.97. The stock has a fifty day moving average price of $0.96 and a 200-day moving average price of $1.01. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The firm has a market cap of $48.11 million, a price-to-earnings ratio of -2.44 and a beta of 0.57.

Institutional Trading of Cytosorbents

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its holdings in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Sargent Investment Group LLC increased its holdings in Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after buying an additional 192,747 shares during the period. Atomi Financial Group Inc. acquired a new position in Cytosorbents in the 3rd quarter worth approximately $51,000. Finally, CM Management LLC lifted its stake in Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after acquiring an additional 25,000 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.